Avalyn Pharma Inc
Veridion Score
Composite trend over time
Why is AVLN moving today?
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for AVLN.
AVLN insider activity
Avalyn Pharma Inc
3 insiders bought in the last 90 days
Net buying: $25.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-01 | Novo Holdings A/S | Insider | buy | $18.00 | 555,555 | 3,883,289 | $10.0M | SEC Form 4 |
| 2026-05-01 | 2026-05-01 | Carroll Jill | Insider | buy | $18.00 | 277,778 | 2,186,562 | $5.0M | SEC Form 4 |
| 2026-05-01 | 2026-05-01 | George Simeon | Insider | buy | $18.00 | 277,777 | 1,122,087 | $5.0M | SEC Form 4 |
| 2026-05-01 | 2026-05-01 | George Simeon | Insider | buy | $18.00 | 277,778 | 2,186,562 | $5.0M | SEC Form 4 |
AVLN contract awards, year to date.
Public federal awards linked to this ticker.
AVLN lobbying filings, year to date.
Registered lobbying filings matched to Avalyn Pharma Inc.